Trials / Completed
CompletedNCT04041011
A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
A Phase Ib Study of SHR-1316 in Combination With Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1.Experimental: A (Part 1): Fluzoparib and SHR -1316 | 1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV). |
| DRUG | 2.Experimental: B (Part 1): Fluzoparib and SHR -1316 | 2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV). |
| DRUG | 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion | 3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV). |
Timeline
- Start date
- 2019-09-17
- Primary completion
- 2021-04-23
- Completion
- 2021-04-23
- First posted
- 2019-08-01
- Last updated
- 2022-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04041011. Inclusion in this directory is not an endorsement.